Pure CBD does not cause hallucinations. Unlike THC, the compound in cannabis responsible for psychoactive effects, CBD does not bind to the brain receptors that produce altered perception, euphoria, or hallucinatory experiences. The CDC states plainly that CBD is “not impairing” and does not cause a “high.” However, there are real-world scenarios where a product labeled as CBD could trigger psychiatric symptoms, and understanding those scenarios is the practical answer most people searching this question need.
Why CBD Doesn’t Produce Hallucinations
Hallucinations from cannabis are linked to THC activating CB1 receptors in the brain. CBD, in its natural form, does not bind to CB1 or CB2 receptors in any meaningful way. Research published in ScienceDirect confirms that natural CBD shows only modest indirect modulation of these receptors, not the direct activation that would alter perception or cause psychotic symptoms.
Clinical trials have actually tested CBD at high doses in people with schizophrenia and other psychotic disorders. In a trial using up to 800 mg per day, CBD reduced positive psychotic symptoms (which include hallucinations and delusions) at rates comparable to a standard antipsychotic medication, with fewer side effects. A separate placebo-controlled trial found that 1,000 mg per day of CBD improved psychotic symptoms significantly compared to placebo. Higher CBD blood levels were associated with fewer psychotic-like symptoms, less anxiety, and less distress. In other words, CBD appears to work against hallucinations, not cause them.
What CBD Side Effects Actually Look Like
At the doses used in clinical settings (200 to 1,000 mg per day, far above typical consumer products), the most common side effects are drowsiness, sedation, diarrhea, and nausea. The FDA-approved CBD medication Epidiolex lists suicidal thoughts, agitation, depression, aggression, and panic attacks as possible psychiatric side effects, similar to warnings on other anti-seizure drugs. Hallucinations are not among them.
One study gave 600 mg of CBD to people with high paranoid traits before placing them in a virtual-reality scenario. CBD had no effect on paranoid thinking and showed a trend toward increased anxiety, but produced no hallucinations or psychotic breaks. Insomnia occurred in a small percentage of participants across trials, at rates similar to placebo.
When a “CBD Product” Actually Contains THC
This is where the real risk lies. Hemp-derived CBD products are legally allowed to contain up to 0.3% THC by dry weight. For most people taking a standard dose, that trace amount is insignificant. But the CBD market is poorly regulated, and what’s on the label doesn’t always match what’s in the bottle.
The bigger concern is a wave of products marketed alongside CBD that contain psychoactive compounds. Delta-8 THC, which is chemically converted from CBD, produces intoxicating effects similar to regular (delta-9) THC. The FDA has warned that some delta-8 products are labeled simply as “hemp products,” leading consumers to assume they’re non-psychoactive. The CDC issued a health advisory in 2021 specifically about CBD being synthetically converted into delta-8 THC. These products can absolutely cause altered perception, anxiety, paranoia, and in vulnerable individuals, hallucinations.
Beyond delta-8, the market now includes potent synthetic cannabinoids derived from CBD. Some of these are full agonists at CB1 receptors, meaning they activate the brain’s cannabinoid system far more powerfully than even regular THC. These substances have been linked to psychiatric crises, seizures, and acute organ injury. A product purchased as “CBD” that actually contains one of these compounds could produce severe psychoactive effects including hallucinations.
CBD Can Amplify Other Medications
CBD is processed by liver enzymes that also break down a long list of common medications. By inhibiting these enzymes, CBD can raise blood levels of drugs you’re already taking, sometimes significantly. This includes tricyclic antidepressants, SSRIs, antipsychotics, beta-blockers, and opioids.
The tricyclic antidepressant amitriptyline is a clear example. CBD inhibits multiple enzymes responsible for clearing it from your body, which can increase side effects like anticholinergic syndrome: confusion, disorientation, and in severe cases, visual hallucinations. So while CBD itself isn’t causing the hallucination, it can be the reason another drug reaches a level where psychiatric side effects emerge. If you take any prescription medication that affects your brain or nervous system, this interaction is worth taking seriously.
People With Psychotic Disorders Face Different Risks
The relationship between CBD and psychosis is more complicated for people with schizophrenia or related conditions. While standalone CBD has shown antipsychotic properties in trials, a 2025 study published in Neuropsychopharmacology found that when people with schizophrenia and cannabis use disorder took CBD before inhaling cannabis, their psychotic symptoms actually worsened compared to placebo pretreatment. Positive symptom scores (the category that includes hallucinations) increased by 5.0 points after CBD pretreatment versus 2.9 points after placebo. CBD also worsened verbal memory impairment in this group.
This doesn’t mean CBD alone caused psychosis. It means the interaction between CBD, THC, and a brain already vulnerable to psychotic symptoms is unpredictable and potentially harmful. For someone with a psychotic disorder, the assumption that CBD is universally protective does not hold up.
How to Verify What’s in Your Product
The single most useful step you can take is checking a product’s certificate of analysis (COA), which reputable brands make available on their website or by QR code on packaging. A COA is a third-party lab report showing exactly what’s in the product. Here’s what to look for:
- Cannabinoid profile: Confirm CBD concentration matches the label. For full-spectrum products, THC should appear below 0.3%. For broad-spectrum or isolate products, THC should read “ND” (not detected).
- No unexpected cannabinoids: The report should not show significant levels of delta-8 THC, THC-O, or other synthetic cannabinoids unless the product is specifically marketed that way.
- Contaminant screening: Heavy metals (arsenic, cadmium, lead, mercury), pesticides, residual solvents, and microbial contamination should all read “ND” or “Pass.”
If a product doesn’t have a COA, or the COA isn’t from an independent lab, that’s a red flag. The absence of third-party testing is the single strongest predictor that a product may not contain what it claims.